

# Reduction of OXidative stress in Chronic Obstructive Pulmonary Disease by Exercise and Nutrition

<b>Submission date</b> 23/08/2007	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 23/08/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/05/2008	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr E.P.A. Rutten

**Contact details**  
Research, Development and Education  
Centre for Integrated Rehabilitation of Organ Failure (CIRO)  
Horn  
Netherlands  
6080 NM  
ericarutten@proteion.nl

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

**Scientific Title**

The effect of nutritional supplementation as adjunct to exercise training on resting and exercise-induced oxidative stress, muscle function and exercise capacity in severe Chronic Obstructive Pulmonary Disease patients

**Acronym**

ROXCEN

**Study objectives**

Daily ingestion of a nutritional supplement enriched with antioxidants during eight weeks pulmonary rehabilitation results in a decreased oxidative stress in rest and after exercise in Chronic Obstructive Pulmonary Disease (COPD) patients compared to an iso-caloric placebo.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics approval received from the Ethical Commission of the METC of Maastricht on the 19th September 2007 (ref: NL17788.068.07/MEC 07-3-066).

**Study design**

Double-blind placebo controlled parallel intervention study

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Chronic Obstructive Pulmonary Disease (COPD)

**Interventions**

Nutritional supplement enriched with antioxidants versus iso-caloric placebo.

**Intervention Type**

Supplement

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Nutritional supplement

**Primary outcome(s)**

To assess the effect of daily ingestion of a nutritional supplement enriched with antioxidants during eight weeks pulmonary rehabilitation on resting and exercise-induced oxidative stress in COPD patients compared to an iso-caloric placebo. Oxidative stress will be measured by specific biomarkers in exhaled air, breath condensate, urine and venous blood, measured at the start of the rehabilitation and after eight weeks.

**Key secondary outcome(s)**

To examine the effects of daily ingestion of a nutritional supplement enriched with antioxidants during pulmonary rehabilitation on respiratory and skeletal muscle strength and exercise capacity in COPD patients, measured at the start of the rehabilitation and after eight weeks.

**Completion date**

01/07/2008

**Eligibility****Key inclusion criteria**

1. Diagnosis of COPD according to the American Thoracic Society (ATS) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (Forced Expiratory Volume in one second [FEV1] less than 60% predicted and FEV1/Forced Vital Capacity [FVC] less than 70% and less than 10% predicted improvement in FEV1 after b2-agonist inhalation
2. Both male and female, age-range from 40 to 75 years
3. No respiratory tract infection or exacerbation of the disease for at least four weeks before the study
4. Capable to provide informed consent
5. Presence of other chronic diseases is allowed in case the clinical status is stable for at least four weeks before the study

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Inability to perform the incremental cycle ergometer test
2. Chronic use of antioxidants or vitamin supplements
3. Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements
4. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
5. Specific allergy or intolerance

**Date of first enrolment**

01/10/2007

**Date of final enrolment**

01/07/2008

**Locations**

**Countries of recruitment**

Netherlands

**Study participating centre**

Research, Development and Education

Horn

Netherlands

6080 NM

## **Sponsor information**

**Organisation**

Numico Research B.V. (The Netherlands)

**ROR**

<https://ror.org/00aj77a24>

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

Numico Research B.V. (The Netherlands)

## **Results and Publications**

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration